- Home
- AVTX vs ADVM Comparison
AVTX vs ADVM Comparison
Compare AVTX & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- ADVM
- Stock Information
- Founded
- AVTX 2011
- ADVM 2006
- Country
- AVTX United States
- ADVM United States
- Employees
- AVTX N/A
- ADVM N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AVTX Health Care
- ADVM Health Care
- Exchange
- AVTX Nasdaq
- ADVM Nasdaq
- Market Cap
- AVTX 57.4M
- ADVM 49.9M
- IPO Year
- AVTX 2015
- ADVM 2014
- Fundamental
- Price
- AVTX $7.89
- ADVM $2.32
- Analyst Decision
- AVTX Strong Buy
- ADVM Strong Buy
- Analyst Count
- AVTX 7
- ADVM 5
- Target Price
- AVTX $31.00
- ADVM $23.80
- AVG Volume (30 Days)
- AVTX 149.3K
- ADVM 121.7K
- Earning Date
- AVTX 08-11-2025
- ADVM 08-11-2025
- Dividend Yield
- AVTX N/A
- ADVM N/A
- EPS Growth
- AVTX N/A
- ADVM N/A
- EPS
- AVTX N/A
- ADVM N/A
- Revenue
- AVTX $441,000.00
- ADVM $1,000,000.00
- Revenue This Year
- AVTX N/A
- ADVM N/A
- Revenue Next Year
- AVTX N/A
- ADVM $18.82
- P/E Ratio
- AVTX $1.17
- ADVM N/A
- Revenue Growth
- AVTX N/A
- ADVM N/A
- 52 Week Low
- AVTX $3.39
- ADVM $1.78
- 52 Week High
- AVTX $16.00
- ADVM $8.56
- Technical
- Relative Strength Index (RSI)
- AVTX 80.64
- ADVM 40.09
- Support Level
- AVTX $6.21
- ADVM $2.61
- Resistance Level
- AVTX $6.89
- ADVM $2.82
- Average True Range (ATR)
- AVTX 0.64
- ADVM 0.21
- MACD
- AVTX 0.17
- ADVM -0.04
- Stochastic Oscillator
- AVTX 78.59
- ADVM 6.90
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.